Skip to content

Improving Chronic Disease Management With Pieces

Improving Chronic Disease Management With Pieces (ICD-Pieces)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02587936
Acronym
ICD-Pieces
Enrollment
18268
Registered
2015-10-27
Start date
2016-07-18
Completion date
2022-10-15
Last updated
2024-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, Diabetes, High BP, Hypertension, Type 2 Diabetes

Keywords

Chronic, Risk prediction model, Quality Improvement (QI), Pragmatic trial, Cluster randomization, Collaborative care, clinical informatics, Chronic kidney disease, hypertension, high BP, diabetes

Brief summary

ICD-Pieces (Parkland Intelligent e-Coordination and Evaluation System) trial is a National Institutes of Health (NIH) Healthcare Systems(HCS) Collaboratory demonstration project to improve management of patients with a triad of Chronic Kidney Disease, hypertension and diabetes with Pieces in four HCS including Parkland, Texas Health Resources (THR), ProHealth Physicians Incorporation and North Texas VA. Pieces is a decision support technology platform created by Parkland Center for Clinical Innovation(PCCI). The primary objective is to test the hypothesis that a collaborative model of primary care and subspecialty care intervention enhanced by Pieces and practice facilitators compared to standard clinical practice will reduce all-cause hospitalizations in patients with coexisting chronic kidney disease, diabetes and hypertension. Secondary objectives are: a)Test if implementation of the collaborative model will reduce 30-day readmissions, emergency room visits, cardiovascular events or deaths and disease-specific hospitalizations; b) Develop and validate risk predictive models for disease-specific hospitalizations, all-cause hospitalizations, 30-day readmissions, emergency room visits, cardiovascular events and deaths for patients with chronic kidney disease, diabetes and hypertension. c) Collect demographic and clinical data to assist phenotyping patients with chronic kidney disease, diabetes and hypertension. d) Obtain safety data including Acute Kidney Injury, progression of chronic kidney disease, electrolyte disturbances and medication errors, and drug toxicity; e) Collect resource utilization information including hospitalizations, emergency room visits, outpatient visits, and diagnostic or therapeutic procedures completed. Candidate patients in selected clinics will be enrolled over a period of 2 years and followed for 12 months. Pieces will ascertain both primary and secondary outcomes from the Electronic Health Record supported with data from the Dallas Fort Worth Hospital Council (DFWHC), Accountable Care Organization (ACO) reports and VA database, and deaths from Social Security Index (SSI) data.

Detailed description

ICD-Pieces is a randomized, pragmatic clinical trial in four large healthcare systems to improve care of patients with coexistent chronic kidney disease, diabetes and hypertension. The investigators hypothesis is that patients who receive care with a collaborative model of primary care-subspecialty care enhanced by novel information technology (Pieces) and practice facilitators will have fewer all-cause hospitalizations, readmissions, disease-specific hospitalizations, Emergency Room visits, cardiovascular events and deaths than patients receiving standard medical care. The investigators will also aim to develop a better understanding of risk predictors in patients with chronic kidney disease, diabetes and hypertension to guide future recommendations of therapies that are tailored to individual patients. The primary objective of the study is to test the hypothesis that a collaborative model of primary care enhanced by novel information technology and practice facilitators will allow to leverage data from electronic health records to identify patients with the triad of chronic kidney disease, diabetes and hypertension using objective and reproducible criteria, and provide clinician support for implementation of best practices of care, monitoring clinical measures, adjusting treatments and reduce 12-month hospitalization rates. In this study disease-specific hospitalizations for chronic kidney disease, diabetes and hypertension include hospitalizations due to cardiovascular complications, congestive heart failure, volume overload, accelerated/malignant/uncontrolled hypertension, acute coronary syndromes, myocardial infarction, stroke, coronary/peripheral revascularization, limb ischemia/amputations, diabetes complications, uncontrolled diabetes, hypoglycemia, acute kidney injury, hyperkalemia, electrolyte disturbances, medication errors, drug toxicity, and infections. Secondary Objectives: The study will test if implementation of the collaborative model of primary care-subspecialty care interventions will reduce 30-day readmissions (for patients who are hospitalized), emergency room visits, cardiovascular events, deaths or disease-specific hospitalizations. In this study disease-specific hospitalizations for chronic kidney disease, diabetes and hypertension include hospitalizations due to cardiovascular complications, congestive heart failure, volume overload, accelerated/malignant/uncontrolled hypertension, acute coronary syndromes, myocardial infarction, stroke, coronary/peripheral revascularization, limb ischemia/amputations, diabetes complications, uncontrolled diabetes, hypoglycemia, acute kidney injury, hyperkalemia, electrolyte disturbances, medication errors, drug toxicity, and infections. 2.) Develop and validate predictive models for risks of hospitalizations, emergency room visits, cardio vascular events and deaths for all patients with coexistent chronic kidney disease, diabetes and hypertension and predict risks of 30-day disease-specific readmissions for patients who are hospitalized. 3.) Capture data (demographic, clinical, medications, laboratories, procedures) to phenotype patients with a triad of chronic kidney disease, diabetes and hypertension. 4.) Obtain important safety data for patients with chronic kidney disease, diabetes and hypertension including adverse safety events, acute kidney injury and progression of chronic kidney disease (even for patients not hospitalized). 5.) Obtain information on resource utilization including not only hospitalizations but also all emergency room visits, outpatient visits and diagnostic and therapeutic procedures. 6.) Evaluate the impact of the collaboratory model of care on patient Reported Outcomes (PROs) including health-related quality of life, patient satisfaction, Patient perspective on quality of their care and measures of patient perception of burden related to care of their chronic kidney disease, diabetes and hypertension. 7.) Evaluate the impact of the collaborative primary care-subspecialty care model on provider satisfaction with resources and ability to manage patients with coexistent chronic kidney disease, diabetes and hypertension. Study Outcome Measures: The primary outcome of this trial is all cause hospitalizations for patients with a triad of chronic kidney disease, diabetes and hypertension. Specifically, the outcome will be hospitalization rates at 12 months for study participants. The investigators will include both regular hospitalizations as defined by Center for Medicaid and Medicare(CMS) and observation status overnight (to avoid variations related to definition of inpatient status/hospitalization using the recent implementation of the two midnight rule CMS-1599-F). Study Design: The study will employ a prospective stratified cluster randomization design. The stratum is each of the four large healthcare systems participating in the study. The unit of randomization will be primary care clinics. In some healthcare systems several primary care clinics share the same geographic location and personnel and they will be randomized as a single unit. The cluster design of the study is best suited to detect important differences in outcomes between the intervention and control groups\[8,55\]. The decision to use primary care clinics as a unit for randomization in the study is based on the ability to implement different models of care in the active intervention sites as compared to the control sites. The collaborative model of care which includes novel information technology, subject identification, facilitation of patient care, monitoring of outcomes and participation from facilitators can be most efficiently applied to the workflow of clinics when they are fully randomized to active intervention. The cluster randomization design with clinics receiving collaborative primary care-subspecialty care versus standard care also limits the risk of cross-contamination between intervention and control groups in the study Primary care practices will be stratified by healthcare systems and randomly allocated to either intervention group or standard medical care group using a randomized permutation block within stratum. Based on the assignment of the clinic where a patient goes, each patient will be assigned either to the intervention group or the standard medical care group. All eligible patients of clinics who are randomized to the study will be included in the comparison of the two intervention groups regardless of intervention compliance (intention-to-treat analysis) to investigate if patients in intervention group have significantly less all-cause hospitalizations than those in the standard medical care group. Evaluation will also be performed to determine treatment effects on disease-specific hospitalizations, emergency room visits, cardiovascular events and deaths. There will be two study groups: active intervention group randomized to the collaborative model of care facilitated by novel information technology and practice facilitators and standard/usual care group. The intervention in the active group is implementation of a collaborative model of care that facilitates delivering best care practices to patients who have coexistent chronic kidney disease, type 2 diabetes and hypertension. The model uses a novel information technology platform called Pieces and practice facilitators with the purpose of allowing for early identification of patients with objective criteria and to implement best practices of care, monitor important clinical measures, adjust treatments and achieve improved outcomes. The intervention will be delivered in the outpatient setting. Data collection for assessment of study objectives will be mainly based on information technology tools to capture data from the electronic health record. Some data fields will require collection of data from Dallas Fort Worth Regional Hospital Council, ProHealth Accountable Care Organization databases, VA of North Texas and Social Security Death Files Index. A Data Safety Monitoring Board (DSMB) has been assembled by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and will oversee study planning and implementation of the study.

Interventions

OTHERCollaborative Model of Primary care and Subspecialty care

Pieces will access Electronic Health Record for all patients receiving care at the participating sites to detect patients with a triad of chronic kidney disease, diabetes and hypertension, facilitate management and monitor outcomes. To maximize successful implementation of care, a Practice Facilitator will be at each site with standardized role training using a curriculum based on the Agency for Healthcare Research and Quality (AHRQ) Practice Facilitation Handbook. Specific interventions are maintaining BP less than 140/90 mmHg, use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), treatment with statins, aiming for glycosylated Hemoglobin (HgA1C) at the recommended target, and avoiding nephrotoxic medications. Additional interventions include chronic kidney disease education for Primary Care Providers (PCP) and patients using National Kidney Disease Education Program (NKDEP) materials.

Sponsors

Parkland Center for Clinical Innovation
CollaboratorOTHER
Parkland Health and Hospital System
CollaboratorOTHER
Texas Health Resources
CollaboratorOTHER
Connecticut Center for Primary Care
CollaboratorOTHER
Dallas VA Research Corporation
CollaboratorINDUSTRY
G-Health Enterprises
CollaboratorOTHER
National Institutes of Health (NIH)
CollaboratorNIH
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* CKD Inclusion Criteria (present at least ≥ 3 months apart) 1. There will be two or more Estimated Glomerular Filtration Rate (eGFRs) calculations less than 60ml/minute (corrected for BSA) or 2. Two or more positive tests for albuminuria and/or proteinuria Albuminuria/proteinuria can be defined by quantitative criteria with albumin/creatinine ratio greater than 30mg/g, urine protein creatinine ratio greater than 200mg/g or positive dipstick with protein detection (adjusted for urinary concentration/specific gravity). * Diabetes Inclusion Criteria Only patients with type 2 diabetes will be enrolled in this study. 1. Random blood glucose greater than 200mg/dL 2. Hemoglobin A1C greater than 6.5% 3. Use of hypoglycemic agents or 4. Type 2 diabetes included in problem list * Hypertension Inclusion Criteria 1. Systolic blood pressure greater than 140 mmHg on two different occasions at least one week apart 2. Diastolic blood pressure greater than 90 on two occasions at least more than one week apart 3. Use of antihypertensive agents except thiazide diuretics or 4. Hypertension included in problem list

Exclusion criteria

*

Design outcomes

Primary

MeasureTime frameDescription
All Cause Hospitalizations for Patients With a Triad of Chronic Kidney Disease, Diabetes and Hypertension12 monthsHospitalization rates at 12 months for all study participants, capturing all cause unplanned hospitalizations including both regular hospitalizations as currently defined by CMS and observation status overnight. Hospitalizations will be ascertained from Electronic Health Record of each participating healthcare system with assistance from Pieces.

Secondary

MeasureTime frameDescription
30-day All Cause Readmissions (for Those Patients Who Have an Index Hospitalization)12 months30-day all-cause readmissions (for those patients who have an index hospitalization), emergency room visits, cardiovascular events and deaths, and disease-specific hospitalizations for cardiovascular complications, congestive heart failure, volume overload, hypertension complications, acute coronary syndrome, myocardial infarction, coronary/peripheral revascularization, stroke, amputation/limb ischemia, uncontrolled diabetes, hypoglycemia, diabetes complications, acute kidney injury, hyperkalemia, electrolyte disturbances, medication errors, drug toxicity, and infections.

Countries

United States

Participant flow

Recruitment details

The study is a pragmatic trial with the participating primary care practices randomized to Intervention or Usual care group

Pre-assignment details

Participants must meet study criteria to include 1. Confirmed diagnosis of triad CKD, DM, and Hypertension 2. Be followed in one of the primary care clinics of the participating health system 3. Should have completed a clinic visit/ Lab no more than 2 years prior to enrollment visit

Participants by arm

ArmCount
Intervention
Group to receive Collaborative model of primary care and subspecialty care enhanced by Pieces and Practice Facilitator Collaborative Model of Primary care and Subspecialty care: Pieces will access Electronic Health Record for all patients receiving care at the participating sites to detect patients with a triad of chronic kidney disease, diabetes and hypertension, facilitate management and monitor outcomes. To maximize successful implementation of care, a Practice Facilitator will be at each site with standardized role training using a curriculum based on the Agency for Healthcare Research and Quality (AHRQ) Practice Facilitation Handbook. Specific interventions are maintaining BP less than 140/90 mmHg, use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), treatment with statins, aiming for glycosylated Hemoglobin (HgA1C) at the recommended target, and avoiding nephrotoxic medications. Additional interventions include chronic kidney disease education for Primary Care Providers (PCP) and patients using National Kidney Disease Education Program (NKDEP) materials.
5,508
Usual Care
Group to receive usual care
5,492
Total11,000

Baseline characteristics

CharacteristicTotalUsual CareIntervention
Age-Adjusted Charlson Comorbidity Score3.6 units on a scale
STANDARD_DEVIATION 1.7
3.4 units on a scale
STANDARD_DEVIATION 1.7
3.7 units on a scale
STANDARD_DEVIATION 1.8
Age, Continuous68.5 years
STANDARD_DEVIATION 10.4
68.9 years
STANDARD_DEVIATION 10.3
68.1 years
STANDARD_DEVIATION 10.4
Blood Pressure
Diastolic Blood Pressure
73.5 mmHg
STANDARD_DEVIATION 11.1
73.4 mmHg
STANDARD_DEVIATION 10.8
73.7 mmHg
STANDARD_DEVIATION 11.2
Blood Pressure
Systolic Blood Pressure
132.8 mmHg
STANDARD_DEVIATION 18.4
132.5 mmHg
STANDARD_DEVIATION 17.9
133.1 mmHg
STANDARD_DEVIATION 18.7
Body Mass Index33.2 kg/m^2
STANDARD_DEVIATION 7.5
33 kg/m^2
STANDARD_DEVIATION 7.4
33.4 kg/m^2
STANDARD_DEVIATION 7.6
Estimated GFR48.7 ml/min/1.73 m^2
STANDARD_DEVIATION 16.2
49.4 ml/min/1.73 m^2
STANDARD_DEVIATION 15.6
48.1 ml/min/1.73 m^2
STANDARD_DEVIATION 16.8
Ethnicity (NIH/OMB)
Hispanic or Latino
2073 Participants944 Participants1129 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
7952 Participants4041 Participants3911 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
975 Participants507 Participants468 Participants
Hemoglobin A1c7.6 percent of HbA1c
STANDARD_DEVIATION 2.1
7.5 percent of HbA1c
STANDARD_DEVIATION 2.1
7.6 percent of HbA1c
STANDARD_DEVIATION 2.1
Proteinuria
>=300 mg/mmol
1034 participants437 participants597 participants
Proteinuria
< 30 mg/mmol
1770 participants840 participants930 participants
Proteinuria
>=30 mg/mmol and < 300 mg/mmol
2295 participants1195 participants1100 participants
Proteinuria
Not reported
5901 participants3020 participants2881 participants
Race/Ethnicity, Customized
Asian
238 Participants137 Participants101 Participants
Race/Ethnicity, Customized
Black
2247 Participants1088 Participants1159 Participants
Race/Ethnicity, Customized
Other
82 Participants46 Participants36 Participants
Race/Ethnicity, Customized
Unknown
372 Participants163 Participants209 Participants
Race/Ethnicity, Customized
White
8061 Participants4058 Participants4003 Participants
Sex: Female, Male
Female
5091 Participants2541 Participants2550 Participants
Sex: Female, Male
Male
5909 Participants2951 Participants2958 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
129 / 5,508148 / 5,492
other
Total, other adverse events
1,426 / 5,5081,475 / 5,492
serious
Total, serious adverse events
1,193 / 5,5081,223 / 5,492

Outcome results

Primary

All Cause Hospitalizations for Patients With a Triad of Chronic Kidney Disease, Diabetes and Hypertension

Hospitalization rates at 12 months for all study participants, capturing all cause unplanned hospitalizations including both regular hospitalizations as currently defined by CMS and observation status overnight. Hospitalizations will be ascertained from Electronic Health Record of each participating healthcare system with assistance from Pieces.

Time frame: 12 months

ArmMeasureValue (NUMBER)
InterventionAll Cause Hospitalizations for Patients With a Triad of Chronic Kidney Disease, Diabetes and Hypertension20.7 percentage of participants hospitalized
Usual CareAll Cause Hospitalizations for Patients With a Triad of Chronic Kidney Disease, Diabetes and Hypertension21.12 percentage of participants hospitalized
Secondary

30-day All Cause Readmissions (for Those Patients Who Have an Index Hospitalization)

30-day all-cause readmissions (for those patients who have an index hospitalization), emergency room visits, cardiovascular events and deaths, and disease-specific hospitalizations for cardiovascular complications, congestive heart failure, volume overload, hypertension complications, acute coronary syndrome, myocardial infarction, coronary/peripheral revascularization, stroke, amputation/limb ischemia, uncontrolled diabetes, hypoglycemia, diabetes complications, acute kidney injury, hyperkalemia, electrolyte disturbances, medication errors, drug toxicity, and infections.

Time frame: 12 months

ArmMeasureValue (NUMBER)
Intervention30-day All Cause Readmissions (for Those Patients Who Have an Index Hospitalization)429 participants
Usual Care30-day All Cause Readmissions (for Those Patients Who Have an Index Hospitalization)433 participants

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026